Nothing Special   »   [go: up one dir, main page]

EE05221B1 - HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod - Google Patents

HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod

Info

Publication number
EE05221B1
EE05221B1 EEP200200411A EEP200200411A EE05221B1 EE 05221 B1 EE05221 B1 EE 05221B1 EE P200200411 A EEP200200411 A EE P200200411A EE P200200411 A EEP200200411 A EE P200200411A EE 05221 B1 EE05221 B1 EE 05221B1
Authority
EE
Estonia
Prior art keywords
hmg
preparing
compositions containing
inorganic salt
coa reductase
Prior art date
Application number
EEP200200411A
Other languages
English (en)
Estonian (et)
Inventor
Richard Creekmore Joseph
Alfred Wiggins Norman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05221(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to EEP200900047A priority Critical patent/EE05586B1/xx
Publication of EE200200411A publication Critical patent/EE200200411A/xx
Publication of EE05221B1 publication Critical patent/EE05221B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200411A 2000-01-26 2000-08-04 HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod EE05221B1 (et)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EEP200900047A EE05586B1 (et) 2000-01-26 2000-08-04 Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
PCT/GB2000/003017 WO2001054669A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Publications (2)

Publication Number Publication Date
EE200200411A EE200200411A (et) 2003-12-15
EE05221B1 true EE05221B1 (et) 2009-10-15

Family

ID=9884259

Family Applications (3)

Application Number Title Priority Date Filing Date
EEP200200411A EE05221B1 (et) 2000-01-26 2000-08-04 HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod
EEP200200052A EE04990B1 (et) 2000-01-26 2000-08-04 HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
EEP200900047A EE05586B1 (et) 2000-01-26 2000-08-04 Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees

Family Applications After (2)

Application Number Title Priority Date Filing Date
EEP200200052A EE04990B1 (et) 2000-01-26 2000-08-04 HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
EEP200900047A EE05586B1 (et) 2000-01-26 2000-08-04 Farmatseutiline kompositsioon, mis sisaldab (E)-7-[4-(4-fluorofenüül)-6-isopropüül-2-[metüül(metüül-sulfonüül)amino]pürimidiin-5-üül]-(3R,5S)-3,5-dihüdroksühept-6-eenhapet v?i selle farmatseutiliseltaktsepteeritavat soola, millel on valguse toime ees

Country Status (48)

Country Link
US (2) US6548513B1 (xx)
EP (6) EP1251831A1 (xx)
JP (3) JP4800467B2 (xx)
KR (3) KR100388713B1 (xx)
CN (3) CN100528161C (xx)
AP (2) AP1879A (xx)
AR (3) AR023624A1 (xx)
AT (3) AT412062B (xx)
AU (5) AU2000264559A1 (xx)
BE (2) BE1013413A3 (xx)
BG (4) BG65234B1 (xx)
BR (2) BR0003365A (xx)
CA (3) CA2313783C (xx)
CH (2) CH700184B1 (xx)
CL (1) CL2007001807A1 (xx)
CR (3) CR6568A (xx)
CZ (3) CZ299105B6 (xx)
DE (3) DE60001371T2 (xx)
DK (3) DK178242B1 (xx)
EE (3) EE05221B1 (xx)
ES (2) ES2171123B1 (xx)
FI (3) FI111806B (xx)
FR (2) FR2804025B1 (xx)
GB (3) GB0001621D0 (xx)
HK (6) HK1036934A1 (xx)
HR (3) HRP20020097B1 (xx)
HU (2) HUP0003111A3 (xx)
IL (4) IL150513A0 (xx)
IS (3) IS1940B (xx)
IT (2) ITTO20000779A1 (xx)
ME (4) MEP33708A (xx)
MY (2) MY123650A (xx)
NL (2) NL1015859C2 (xx)
NO (4) NO312434B1 (xx)
NZ (2) NZ519774A (xx)
PL (2) PL341855A1 (xx)
PT (3) PT102504A (xx)
RS (1) RS50201B (xx)
RU (2) RU2206324C1 (xx)
SE (2) SE523481C2 (xx)
SI (1) SI1223918T1 (xx)
SK (2) SK283872B6 (xx)
TR (3) TR200201888T2 (xx)
TW (2) TW553749B (xx)
UA (2) UA51853C2 (xx)
WO (2) WO2001054668A1 (xx)
YU (1) YU52902A (xx)
ZA (2) ZA200003997B (xx)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
PT1274401E (pt) † 2000-04-10 2011-12-02 Teva Pharma Composições farmacêuticas estáveis contendo ácidos 7-substituídos-3,5-di-hidroxi-heptanóicos ou ácidos 7-substituídos-3,5-di-hidroxi-heptenóicos
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US20060039967A1 (en) * 2002-08-12 2006-02-23 Motohiro Ohta Amino acid-containing chewable
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
US7396927B2 (en) * 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
PT3260117T (pt) * 2003-09-12 2019-07-04 Amgen Inc Formulação de dissolução rápida compreendendo cinacalcet hcl
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) * 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
TW201240679A (en) * 2004-03-12 2012-10-16 Capsugel Belgium Nv Pharmaceutical formulations
WO2005107722A2 (en) * 2004-05-04 2005-11-17 Rhodia Inc. Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
KR101020024B1 (ko) * 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
MX2008001597A (es) * 2005-08-04 2008-04-04 Transform Pharmaceuticals Inc Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.
TW200800917A (en) * 2005-08-16 2008-01-01 Teva Pharma Crystalline rosuvastatin intermediate
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
UA92920C2 (ru) * 2005-10-31 2010-12-27 Кова Ко., Лтд. Таблетка с насечкой, включающая питавастатин, и имеющая превосходную фотостабильность
US20090093499A1 (en) * 2005-12-20 2009-04-09 Lek Pharmaceuticals D.D. Pharmaceutical composition
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
HUE027872T2 (en) * 2006-05-03 2016-11-28 Msn Laboratories Private Ltd A novel process for statins and their pharmaceutically acceptable salts
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
ES2567171T3 (es) * 2006-10-09 2016-04-20 Msn Laboratories Private Limited Nuevo procedimiento para la preparación de estatinas y sus sales farmacéuticamente aceptables
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
US20110003837A1 (en) * 2008-01-30 2011-01-06 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
AU2009256572A1 (en) * 2008-06-13 2009-12-17 Capsugel Belgium Nv Hydroxypropyl cellulose capsule shell
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
ES2657416T3 (es) * 2008-06-27 2018-03-05 Krka, Torvarna Zdravil, D.D., Novo Mesto Composición farmacéutica que comprende una estatina
TR201101807T2 (tr) * 2008-06-27 2012-02-21 Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@ Rosuvastatin kalsiyumun farmasotik bileşimleri
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
AU2010281913A1 (en) 2009-08-13 2012-04-05 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
WO2011139256A2 (en) 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
JP5988963B2 (ja) * 2011-04-12 2016-09-07 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
MX353847B (es) * 2011-05-20 2018-01-31 Astrazeneca Uk Ltd Composicion farmaceutica de rosuvastatina calcica.
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
US10952968B2 (en) * 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
JP2016514125A (ja) 2013-03-12 2016-05-19 エルジー・ライフ・サイエンシーズ・リミテッドＬＧ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3219318A4 (en) * 2014-11-11 2018-07-11 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable with respect to light
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
EP3364946A4 (en) 2015-10-23 2019-06-26 Lyndra, Inc. STOMACH DISTRIBUTION SYSTEMS FOR DELAYED RELEASE OF THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
WO2017205844A2 (en) 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
CA3038557A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
CA3066658A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
ES2064887T3 (es) 1990-09-13 1995-02-01 Akzo Nobel Nv Composiciones quimicas solidas estabilizadas.
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
SG45369A1 (en) 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
IL121565A (en) * 1995-12-22 2002-02-10 Kowa Co Stabilized pharmaceutical preparations containing derivatives of acid (E) -3,5-DIHYDROXY-7- [4 (-4) -FLUOROPHENYL-2 (CYCLOPROPYL-QUINOLIN-3 (-YL] -6-HEPTENOIC
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
CN1144598C (zh) 1998-06-05 2004-04-07 沃尼尔·朗伯公司 利用氧化镁稳定的含ace抑制剂的组合物
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001054688A1 (en) 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
BG65234B1 (bg) 2007-09-28
SE523481C2 (sv) 2004-04-20
MY122707A (en) 2006-04-29
CH691347A5 (de) 2001-07-13
NZ531474A (en) 2007-04-27
CA2315141C (en) 2009-08-18
NZ519774A (en) 2004-04-30
DE60001371D1 (de) 2003-03-13
NO20071303L (no) 2001-07-27
IL147870A0 (en) 2002-08-14
EP2133070A1 (en) 2009-12-16
YU5202A (sh) 2004-12-31
IS6254A (is) 2002-01-29
AU781269C (en) 2006-11-30
CN1282581A (zh) 2001-02-07
HK1047052A1 (zh) 2003-02-07
US6548513B1 (en) 2003-04-15
JP3267960B2 (ja) 2002-03-25
TWI228050B (en) 2005-02-21
HU0003111D0 (en) 2000-10-28
IL150513A0 (en) 2003-02-12
DE10038110B4 (de) 2006-06-29
CA2639407C (en) 2011-09-13
CA2313783C (en) 2002-03-12
CN1319396A (zh) 2001-10-31
SE0002826D0 (sv) 2000-08-04
GB0019029D0 (en) 2000-09-27
BR0003364A (pt) 2001-09-18
PL341855A1 (en) 2001-07-30
BE1013413A3 (fr) 2001-12-04
AU2005202392C1 (en) 2016-06-02
AU2005202392A1 (en) 2005-06-30
ITTO20000779A1 (it) 2002-02-04
CA2639407A1 (en) 2001-07-26
FI20001749A (fi) 2001-07-27
NL1015859A1 (nl) 2001-07-27
CN1149997C (zh) 2004-05-19
HRP20020632A2 (en) 2004-12-31
JP4800988B2 (ja) 2011-10-26
UA51853C2 (uk) 2002-12-16
NO312434B1 (no) 2002-05-13
RS50201B (sr) 2009-07-15
CA2315141A1 (en) 2001-07-26
AU5184200A (en) 2001-08-02
FI20105657A (fi) 2010-06-10
ITTO20000779A0 (it) 2000-08-04
EP2266540A1 (en) 2010-12-29
EE05586B1 (et) 2012-10-15
DK200001170A (da) 2001-01-27
BG66159B1 (bg) 2011-09-30
NO20003968L (no) 2001-07-27
FI111806B (fi) 2003-09-30
NL1015858C2 (nl) 2001-07-27
UA77156C2 (en) 2006-11-15
HK1048950A1 (zh) 2003-04-25
CZ299105B6 (cs) 2008-04-23
TW553749B (en) 2003-09-21
SK11792000A3 (sk) 2001-12-03
MEP33708A (en) 2010-10-10
HUP0003111A2 (hu) 2002-02-28
FR2795324B1 (fr) 2002-05-17
DK178242B1 (da) 2015-09-28
EP1251831A1 (en) 2002-10-30
ES2171123B1 (es) 2003-11-16
ES2155043A1 (es) 2001-04-16
CR6687A (es) 2005-07-18
HRP20080525A2 (en) 2008-12-31
SK11782000A3 (sk) 2001-12-03
AU2005202392B2 (en) 2008-11-20
JP2007182452A (ja) 2007-07-19
EP2774609A1 (en) 2014-09-10
MY123650A (en) 2006-05-31
CZ290167B6 (cs) 2002-06-12
HRP20020097B1 (en) 2010-12-31
NL1015859C2 (nl) 2001-10-16
AU5184100A (en) 2001-08-02
JP4800467B2 (ja) 2011-10-26
ME00191B (me) 2010-10-10
BG106926A (bg) 2003-04-30
NO20003968D0 (no) 2000-08-04
PL196808B1 (pl) 2008-02-29
FI121589B (fi) 2011-01-31
GB0001621D0 (en) 2000-03-15
FI20001750A0 (fi) 2000-08-04
EP1223918A1 (en) 2002-07-24
JP2001206847A (ja) 2001-07-31
DE10038108A1 (de) 2001-08-02
EP2018853A1 (en) 2009-01-28
AP1449A (en) 2005-07-28
KR20000072135A (ko) 2000-12-05
AR025055A1 (es) 2002-11-06
AU6580000A (en) 2001-08-07
KR20010077840A (ko) 2001-08-20
AU781269B2 (en) 2005-05-12
IS1940B (is) 2004-07-16
NO327554B1 (no) 2009-08-10
AU2000264559A1 (en) 2001-08-07
IL147870A (en) 2003-10-31
BG106393A (en) 2002-07-31
SE0002826L (sv) 2001-07-27
AP1879A (en) 2008-08-14
EE200200052A (et) 2003-04-15
PL341853A1 (en) 2001-01-29
HK1036935A1 (en) 2002-01-25
HU0003110D0 (en) 2000-10-28
BG110353A (en) 2009-09-30
AR060248A2 (es) 2008-06-04
CR10114A (es) 2008-08-21
YU52902A (sh) 2006-01-16
NO20003967D0 (no) 2000-08-04
BE1013414A5 (fr) 2001-12-04
CZ298411B6 (cs) 2007-09-26
KR20030036492A (ko) 2003-05-09
GB2358583A (en) 2001-08-01
TR200701171T2 (tr) 2007-04-24
CL2007001807A1 (es) 2008-01-18
CN100528161C (zh) 2009-08-19
GB2358582A (en) 2001-08-01
FR2804025B1 (fr) 2002-08-23
HUP0003110A2 (hu) 2001-05-28
RU2002122752A (ru) 2004-03-10
CZ20002883A3 (cs) 2000-10-11
GB2358582B (en) 2004-09-29
IL187416A0 (en) 2008-02-09
PT102503B (pt) 2004-02-27
PT1223918E (pt) 2003-06-30
PT102504A (pt) 2001-07-31
ATA13602000A (de) 2004-02-15
SK283872B6 (sk) 2004-03-02
IS2805B (is) 2012-09-15
PT102503A (pt) 2000-12-29
EE200900047A (et) 2011-04-15
MEP33808A (en) 2010-10-10
RU2206324C1 (ru) 2003-06-20
AU738074B2 (en) 2001-09-06
ZA200003997B (en) 2000-08-14
ATE232088T1 (de) 2003-02-15
AT412062B (de) 2004-09-27
NO20003967L (no) 2001-07-27
IL150513A (en) 2012-12-31
IS6480A (is) 2002-07-23
HK1200368A1 (en) 2015-08-07
FR2804025A1 (fr) 2001-07-27
ITTO20000780A1 (it) 2000-11-04
ME00202B (me) 2010-10-10
ATA13612000A (de) 2004-02-15
KR100698333B1 (ko) 2007-03-23
NO327675B1 (no) 2009-09-07
HUP0003110A3 (en) 2003-02-28
CZ20002884A3 (cs) 2001-09-12
KR100388713B1 (ko) 2003-06-25
FI121365B (fi) 2010-10-29
NO2010005I1 (no) 2010-05-03
CA2313783A1 (en) 2000-10-16
CN101028268A (zh) 2007-09-05
EE04990B1 (et) 2008-04-15
DK200001171A (da) 2001-07-27
AR023624A1 (es) 2002-09-04
GB2358583B (en) 2002-02-06
EE200200411A (et) 2003-12-15
HK1040936B (zh) 2010-06-11
TR200201888T2 (tr) 2002-11-21
AT412063B (de) 2004-09-27
GB0019028D0 (en) 2000-09-27
ES2155043B1 (es) 2001-12-01
WO2001054669A1 (en) 2001-08-02
HK1036934A1 (en) 2002-01-25
BR0003365A (pt) 2001-09-18
SE0002827D0 (sv) 2000-08-04
CR6568A (es) 2004-03-05
ES2171123A1 (es) 2002-08-16
SI1223918T1 (en) 2003-06-30
HRP20020632B1 (en) 2010-12-31
TR200200270T2 (tr) 2002-06-21
HUP0003111A3 (en) 2003-03-28
HRP20020097A2 (en) 2002-06-30
DE10038110A1 (de) 2001-08-23
BG66168B1 (bg) 2011-10-31
DK1223918T3 (da) 2003-04-28
HU222578B1 (hu) 2003-08-28
CH700184B1 (de) 2010-07-15
FI20001750A (fi) 2001-07-27
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
DE60001371T2 (de) 2004-01-22
JP2001206877A (ja) 2001-07-31
RU2264210C2 (ru) 2005-11-20
FR2795324A1 (fr) 2000-12-29
FI20001749A0 (fi) 2000-08-04
AP2002002409A0 (en) 2002-03-31
IS8620A (is) 2007-03-07
SE0002827L (sv) 2001-07-27
EP1223918B1 (en) 2003-02-05
AP2002002591A0 (en) 2002-09-30
ZA200003998B (en) 2000-08-14
HK1040936A1 (en) 2002-06-28
SE523471C2 (sv) 2004-04-20

Similar Documents

Publication Publication Date Title
EE05221B1 (et) HMG-CoA reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, mitmevalentse katiooniga anorgaanilise soola kasutamine ja stabiliseeritud farmatseutilise kompositsiooni valmistamismeetod
EE200300054A (et) Kinaasi inhibiitoritena toimivad bitsüklopürasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
ATE449079T1 (de) Pharmazeutische zusammensetzungen beinhaltend kristallsalze von 7-ä4-(4-fluorophenyl)-6- isopropyl-2-
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
EE200200576A (et) Oksasooli derivaadid ja nende kasutamine türosiini kinaasi inhibiitoritena
NO20032425D0 (no) Nye krystallformer av atorvastatin-hemi-kalsium og fremgangsmåter for deresfremstilling, samt nye fremgangsmåter for fremstilling av andreformer
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
HUP0402454A3 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases, process for their preparation and pharmaceutical compositions containing them
HUP0103007A3 (en) New salts of hmg-coa reductase inhibitors and process for their preparation
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
EE200300227A (et) P38 kinaasiga seotud haigusseisundite ravimeetodid ja kinaasi inhibiitoritena kasulikud pürrolotriasiiniühendid
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
NO923089D0 (no) Tetrahydroindazol, tetrahydrocyklopentapyrazol og heksahydrocykloheptapyrazol forbindelser og deres anvendelse som hmg-coa reduktase-hemmere
AU2003302238A1 (en) 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
EE04717B1 (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
AU2002313655A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl)-succinic acid derivatives as factor viia inhibitors
NO20043919L (no) Fremgangsmate for fremstilling av HMG-COA reduktaseinhiberende mevalonsyrederivater
NO326689B1 (no) Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20101231